Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes
Retrieved on:
Monday, August 22, 2022
Other Consumer, Manufacturing, Women, Teens, Parenting, Men, Children, Baby, Maternity, Family, Medical Devices, Consumer, Consumer Electronics, Technology, General Health, FDA, Diabetes, Other Manufacturing, Health, Glycated hemoglobin, Technology, POD, Caregiver, Ageing, Bonnie Sherr Klein, Dexcom, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, Time, Doctor of Philosophy, G6, Food, Corporation, AID, Medical director, Insulin, CGM, Company, FDA, T1D, Diabetes, Hypoglycemia, 5, Automated insulin delivery systems, Family, Medical device, FRACP
Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.
Key Points:
- Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.
- Omnipod 5 has allowed our family to think less about diabetes, said Kara Hornbuckle, an Omnipod 5 user with two children also using the system.
- in Diabetes Care 4,Omnipod 5 significantly improved time in range, and reduced HbA1c and time in hypoglycemia (
- Omnipod, Omnipod 5, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.